查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1964167

孤儿药市场－全球产业规模、份额、趋势、机会和预测：按药物类型、疾病类型、分销管道、地区和竞争格局划分，2021-2031年

Orphan Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Drug Type, By Disease Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球孤儿药市场预计将从 2025 年的 2,125.9 亿美元成长到 2031 年的 4,430.7 亿美元，复合年增长率为 13.02%。

该市场主要由针对罕见疾病（通常病情严重）的特效药物组成，这些疾病影响的患者群体有限。该领域的成长主要得益于监管激励措施，例如市场独占权和税额扣抵，以及基因组学的进步，这些进步使得标靶治疗成为可能。这些进步旨在弥合患者照护的巨大差距。根据美国製药商协会 (PhRMA) 预测，到 2024 年，在已知的约 7000 种罕见疾病中，只有 5% 的疾病能够获得治疗方法，这表明存在巨大的未满足需求。这种情况正在推动持续的投资和创新。

市场概览
预测期 2027-2031
市场规模：2025年 2125.9亿美元
市场规模：2031年 4430.7亿美元
复合年增长率：2026-2031年 13.02%
成长最快的细分市场 生物
最大的市场 北美洲

儘管取得了这些进展，但高昂的治疗费用仍然是市场成长的主要障碍，也使全球报销流程变得复杂。支付者越来越关注这些小众治疗方法的溢价，导致谈判缺日持久，病人就医延迟。鑑于大量昂贵的先进治疗方法涌入市场，如何在维持创新奖励和控制医疗预算之间取得平衡，使得这场衝突尤为突出。因此，如何成功克服这些财务障碍，仍然是业内相关人员面临的重大挑战。

市场驱动因素

政府奖励措施和孤儿药法规的实施是全球孤儿药市场的主要驱动力。监管机构透过提供实质激励措施，例如临床试验税额扣抵、处方药用户费用豁免以及延长商业性独占期，来降低开发罕见疾病治疗方法相关的商业风险。这些诱因从根本上改变了药物研发的经济模式，鼓励药厂开发那些原本在经济上不可行治疗方法。这些政策的成功体现在监管核准记录中。根据美国食品药物管理局（FDA）于2024年1月发布的《2023年新疗法核准报告》，2023年核准的55种新药中有28种被认定为孤儿药，这表明优先考虑罕见疾病治疗创新的这一框架卓有成效。

同时，基因组学和精准医疗技术的进步正在重塑市场格局，加速开发罕见疾病潜在遗传因子的高标靶化治疗方法。识别特定生物标记和基因突变的能力使製造商能够开发根治性治疗方法，例如基因疗法，而不仅仅是控制症状。这项技术进步吸引了大量投资，并催生了突破性产品。根据再生医学联盟于2024年1月发布的《产业趋势简报》，2023年有五种用于治疗罕见疾病的新型基因疗法获得监管机构核准，创下该领域的新纪录。这些特药的商业性成功也得到了Astra Zeneca在2024年报告称，其罕见疾病业务在2023年创造了77.6亿美元的收入，年增12%，这主要得益于市场对这些先进疗法的需求。

市场挑战

高昂的治疗费用以及由此导致的复杂报销流程是全球孤儿药市场成长的主要障碍。儘管研发公司为了收回巨额研发投入而设定高价，但全球医疗保险公司日益关注药物的成本效益和临床价值。这种财务摩擦迫使企业采取严格的成本控制策略和漫长的价格谈判，实际上导致监管核准与实际市场准入脱钩。如果保险覆盖被延迟或拒绝，企业将面临“上市空檔期”，即已通过核准产品无法产生收入，导致即使存在临床解决方案，市场规模也会萎缩。

这种充满挑战的环境迫使製造商应对难以预测的时间表，从而削弱了小众治疗方法的商业性可行性。据欧洲製药工业协会联合会（EFPIA）称，这些行政和财务障碍导致到2024年，欧洲患者获得创新药物的平均等待时间为578天。如此漫长的等待直接缩短了可用于投资回收的市场独占期。因此，难以确保及时获得报销，使得相关人员不愿优先考虑在价格敏感地区推出产品，最终限制了该行业的全球扩张和财务表现。

市场趋势

将人工智慧 (AI) 应用于孤儿药研发，从根本上加速了针对医疗数据有限的疾病的治疗标靶的发现。透过使用机器学习演算法分析复杂的生物资料集，研发人员可以比传统方法更快预测药物的疗效和安全性，从而显着降低孤儿药研发中通用的高失败率。这种技术有效性的展现，正推动大规模资本投资涌入专注于特定适应症的AI原生生物技术公司。例如，2024年8月，Healx在一份题为「Healx宣布完成4700万美元C轮资金筹措」的新闻稿中宣布，该公司已获得4700万美元资金，用于推进其针对罕见癌症、肾臟疾病和神经发育障碍的旗舰AI驱动药物研发管线，特别是将其针对1型神经纤维瘤的旗舰项目推进至IIAI驱动药物。

同时，策略性併购和授权协议的激增正在重塑竞争格局，大型製药企业正寻求透过风险较低的后期罕见疾病资产快速强化其产品组合。产业领导者不再仅仅依赖内部药物研发週期，而是透过收购专业生技公司，即时获得有前景的治疗方法，以满足尚未满足的医疗需求。这种整合策略的典型例子是针对严重创新疗法的高价值交易。在2024年2月发布的公告「诺华透过收购MorphoSys AG加强肿瘤产品线」中，诺华宣布以27亿欧元收购MorphoSys，从而获得perabrecib（一种治疗骨髓纤维化——一种罕见骨髓癌的创新疗法）的全球独家权益。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球孤儿药市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物类型（生物製药、非生物製药）
    • 疾病类型（肿瘤科、血液科、神经科、循环系统、其他）
    • 分销管道（医院、药局、线上销售、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美孤儿药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲孤儿药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区孤儿药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲孤儿药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲孤儿药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球孤儿药市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • GSK plc
  • Alexion Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Merck KgaA
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23861

The Global Orphan Drugs Market is projected to expand from USD 212.59 Billion in 2025 to USD 443.07 Billion by 2031, exhibiting a CAGR of 13.02%. This market consists of specialized medications designed for rare and typically severe disorders that affect limited patient populations. The sector's growth is largely fueled by regulatory incentives, such as market exclusivity and tax credits, alongside advancements in genomics that facilitate targeted therapies. These developments aim to fill critical gaps in patient care; according to the Pharmaceutical Research and Manufacturers of America, in 2024, treatments were available for only 5% of the approximately 7,000 known rare diseases, creating a widespread unmet need that drives sustained investment and innovation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 212.59 Billion
Market Size 2031USD 443.07 Billion
CAGR 2026-203113.02%
Fastest Growing SegmentBiological
Largest MarketNorth America

Despite these advancements, the high cost of treatment presents a major hurdle to market growth by complicating global reimbursement processes. Payers are increasingly examining the premium pricing of these niche therapies, resulting in extended negotiations that delay patient access. This conflict between maintaining incentives for innovation and managing healthcare budgets is particularly intense given the influx of expensive advanced therapies. Consequently, successfully navigating these financial barriers remains a significant challenge for stakeholders within the industry.

Market Driver

The implementation of favorable government incentives and Orphan Drug Acts serves as the primary catalyst for the Global Orphan Drugs Market. Regulatory bodies mitigate the commercial risks involved in developing treatments for small patient populations by providing substantial benefits, including tax credits for clinical trials, prescription drug user fee waivers, and extended periods of market exclusivity. These incentives fundamentally transform the economic model of drug development, encouraging pharmaceutical companies to pursue therapies that might otherwise be financially impractical. The success of these policies is highlighted by regulatory outcomes; according to the FDA's "New Drug Therapy Approvals 2023" report from January 2024, 28 of the 55 novel drugs approved in 2023 were designated as orphan drugs, emphasizing the effectiveness of these frameworks in prioritizing rare disease innovation.

Concurrently, advancements in genomics and precision medicine technologies are reshaping the market by facilitating the development of highly targeted therapies that address the underlying genetic causes of rare conditions. The capacity to identify specific biomarkers and genetic mutations allows manufacturers to create curative treatments, such as gene therapies, rather than simply managing symptoms. This technological evolution has drawn significant investment and produced breakthrough products; the Alliance for Regenerative Medicine reported in their January 2024 "State of the Industry Briefing" that regulators approved five new gene therapies for rare disorders in 2023, setting a record for the sector. The commercial success of these specialized medicines is further evidenced by major industry players, such as AstraZeneca, which reported in 2024 that its rare disease business generated $7.76 billion in revenue during 2023, a 12% increase driven by demand for these advanced therapeutics.

Market Challenge

The high cost of treatment and subsequent complications in reimbursement processes create a significant barrier to the Global Orphan Drugs Market's growth. As developers establish premium prices to recoup substantial research investments, healthcare payers worldwide are increasingly scrutinizing the clinical value relative to the expense. This financial friction demands rigorous cost containment strategies and prolonged price negotiations, effectively disconnecting regulatory approval from actual market entry. When coverage is delayed or denied, companies encounter a substantial launch gap where approved products fail to generate revenue, thereby reducing the addressable market size despite the availability of a clinical solution.

This difficult environment compels manufacturers to deal with unpredictable timelines that compromise the commercial viability of niche therapies. According to the European Federation of Pharmaceutical Industries and Associations, the average waiting time for patients to access innovative new medicines across Europe reached 578 days in 2024 due to these administrative and financial obstacles. Such lengthy delays directly shorten the market exclusivity period available for recovering investments. Consequently, the challenge of securing timely reimbursement deters industry stakeholders from prioritizing launches in price-sensitive regions, which ultimately restricts the sector's global expansion and financial performance.

Market Trends

The integration of artificial intelligence into rare disease drug discovery is fundamentally accelerating the identification of therapeutic targets for conditions with limited medical data. By utilizing machine learning algorithms to analyze complex biological datasets, developers can predict drug efficacy and safety profiles more quickly than traditional methods permit, significantly lowering the high attrition rates common in orphan drug research. This technological validation is stimulating substantial capital investment in AI-native biotech firms focused on niche indications. For instance, according to a press release from Healx in August 2024 regarding its "Healx Announces $47 million Series C Financing," the company secured $47 million to advance its AI-enabled pipeline of medicines for rare oncology, renal, and neurodevelopmental disorders, specifically moving its lead program for neurofibromatosis Type 1 into Phase 2 clinical trials.

Simultaneously, a surge in strategic mergers, acquisitions, and licensing agreements is reshaping the competitive landscape as major pharmaceutical companies aim to rapidly strengthen their portfolios with de-risked, late-stage rare disease assets. Instead of relying solely on internal discovery timelines, industry leaders are acquiring specialized biotechs to gain immediate access to promising therapies that address significant unmet needs. This consolidation strategy is illustrated by high-value transactions targeting novel treatments for severe conditions; according to a February 2024 announcement titled "Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG," Novartis entered an agreement to acquire MorphoSys for €2.7 billion to obtain exclusive worldwide rights to pelabresib, a novel treatment for the rare bone marrow cancer myelofibrosis.

Key Market Players

  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • GSK plc
  • Alexion Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Merck KgaA
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.

Report Scope

In this report, the Global Orphan Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orphan Drugs Market, By Drug Type

  • Biological
  • Non-biological

Orphan Drugs Market, By Disease Type

  • Oncology
  • Haematology
  • Neurology
  • Cardiovascular
  • Others

Orphan Drugs Market, By Distribution Channel

  • Hospital
  • Pharmacy
  • Online Sales
  • Others

Orphan Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orphan Drugs Market.

Available Customizations:

Global Orphan Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orphan Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Biological, Non-biological)
    • 5.2.2. By Disease Type (Oncology, Haematology, Neurology, Cardiovascular, Others)
    • 5.2.3. By Distribution Channel (Hospital, Pharmacy, Online Sales, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Orphan Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Disease Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Orphan Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Orphan Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Disease Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Orphan Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Disease Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Orphan Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Orphan Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Orphan Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Orphan Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Orphan Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Disease Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Orphan Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Disease Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Orphan Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Orphan Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Orphan Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Orphan Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Orphan Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Orphan Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Orphan Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Orphan Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Disease Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Orphan Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Disease Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Orphan Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Disease Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Orphan Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Orphan Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Orphan Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Orphan Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Orphan Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Sanofi SA
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. GSK plc
  • 15.6. Alexion Pharmaceuticals, Inc.
  • 15.7. AbbVie Inc.
  • 15.8. Merck KgaA
  • 15.9. Johnson & Johnson
  • 15.10. F. Hoffmann-La Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer